VEGFA and age-related macular degeneration: What makes this gene therapy stand out is the use of AAV2.7m8, the evolved capsid that is strongly tropic to photoreceptors.185 Current phase I clinical trials aim to assess safety and tolerability of a single intravitreal injection in patients with AMD, correction of visual acuity, and the elimination of anti-VEGF rescue injections (NCT03748784).